PRODUCT NEwS
INTRAPhARm gUARANTEES SUPPly Of ▼INhIXA (ENOXAPARIN SODIUm)
Intrapharm laboratories have announced that a full supply of Inhixa (Enoxaparin Sodium) to the U.k. market is guaranteed. In recent months, the low molecular weight heparin market (lmwh) has seen considerable supply disruption and volatility, which has placed hospitals and pharmacies in the position of managing scarce supplies.
Intrapharm launched Inhixa (Enoxaparin Sodium), the first biosimilar of Enoxaparin Sodium, indicated for VTE prophylaxis and DVT treatment to the U.k. market in September 2017
Inhixa (Enoxaparin Sodium) is available from AAh, Phoenix and movianto, in 5 presentations in packs of 10 prefilled syringes with active needle guard.
RENNIE hEARTBURN
Rennie heartburn, Indigestion & wind Relief is a triple combination tablet which tackles three of the most common digestive health ailments.
The chewable, mint flavoured tablet gives fast and effective relief day or night, and is being supported by a multi-channel marketing campaign this autumn/winter.
DERmAlEX
Skincare brand Dermalex is making its TV campaign debut as parent company, Perrigo, makes its largest marketing investment yet on the brand. The TV campaign will be on screens for six weeks from 23rd October to 20th November.
As well as the adverts, Dermalex is partnering with key influencers including independent pharmacy consultant Dr Christine Clark, bloggers and vloggers. A facebook page has also been launched where customers can find expert help and advice. Oct 2015. Sample of 261.
The triple relief treatment contains antacids calcium and magnesium carbonate which act directly on the cause of the problem and create a rapid and powerful neutralising action which turns excess stomach acid into water. whilst simethicone, an anti-foaming agent, causes gas bubbles to join and gently disperse the trapped gas easing any trapped wind. The formulation acts physically rather than by entering the bloodstream and can be taken during pregnancy or whilst breastfeeding.
Research shows that more than half (52%) of consumers who experience heartburn and indigestion symptoms are also affected by wind, yet 62% of these don’t seek treatment. Rennie’s triple relief formula is designed to be a convenient and complete solution to relieve all the symptoms at once, helping to minimise the physical and emotional impact on the consumer’s life.
for stock enquiries contact Ceuta healthcare on 0844 243 6661. RRP £2.49 (12s) and £4.25 (24s). Visit the refreshed Rennie website (
rennie.co.uk) for more information.
EPISTATUS® 10 mg OROmUCOSAl SOlUTION mIDAzOlAm ThEAlOz® DUO gEl
OffERS NIghT TImE SOlUTION fOR DRy EyE
Thealoz® Duo gel is a new gel based dry eye drop from Thea Pharmaceuticals that is formulated to extend the ocular surface residence time1 of the innovative Thealoz® Duo artificial tear introduced earlier this year. This prolonged effect makes it ideal for night time use, in conjunction with Thealoz Duo for use through the day.
Thealoz Duo is a clinically proven2,3 eye drop for the treatment of dry eye and combines Sodium hyaluronate with Trehalose, a natural disaccharide which uniquely protects cell membranes from extreme dryness and improves residence time on the ocular surface4.
The addition of carbomer 0.25% (lubricant gel) in Thealoz Duo gel has been shown to significantly extend the increase in tear film thickness5 when compared with gels containing only hyaluronic acid or polyethylene glycol, meaning less frequent instillation is needed.
Thealoz Duo gel and Thealoz Duo are preservative free. Thealoz Duo gel 30 unit doses RRP is £10.99 and Thealoz Duo 10ml RRP is £13.99. Both products are also available on prescription.
PIP CODE: 396-9359 42 - PhARmACy IN fOCUS 392-7412
Veriton Pharma (formerly Special Products ltd) is pleased to announce that Epistatus®
10 mg Oromucosal
Solution, midazolam, is now available to prescribe. The NhS price for a single 10mg in 1ml prefilled syringe is £45.76. Epistatus®
is licensed
for use in the treatment of prolonged, acute convulsive seizures in children and adolescents aged 10 to less than 18 years, who have been diagnosed with epilepsy1
. Buccal midazolam is recommended by NICE2 for the management of
prolonged acute convulsive seizures, and is preferred by most patients and carers compared to the administration of rectal diazepam 3,4.
Epistatus is presented “ready-to-use” in a novel, pre-filled, single-dose syringe, to provide carers with the confidence that they are administering the correct dose1,5
. The pre-filled syringe is contained within a specially-designed, secure
and tamper-evident protective packaging. Dr Rohit Shankar fRCPsych, Consultant in Adult Developmental Neuropsychiatry – CfT and hon. Associate Clinical Professor - Exeter medical School commented: “The importance of having an alternate licensed preparation for use in the treatment of prolonged, acute convulsive seizures, especially in a different mode of delivery is an asset to both clinicians and patients". In response to market research and insights, Veriton Pharma has invested heavily in the development of this new bespoke syringe, which is designed to allow simple administration of the dose into the buccal cavity5
. Community Pharmacists can obtain Epistatus® 10mg/1ml pre-
filled syringes exclusively via Alliance
healthcare.hospitals can order Epistatus® 10mg/1ml pre-filled syringes directly from Veriton Pharma
www.veritonpharma.com.
for further information on Epistatus 10 mg oromucosal midazolam pre-filled syringes, please visit
www.epistatus.co.uk. References available on request.
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48
